title: Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases.
abstract: OBJECTIVE
  To analyze outcomes after interstitial brachytherapy of facial periorificial skin carcinomas.
  
  
  METHODS
  We performed a retrospective analysis of 97 skin carcinomas (88 basal cell carcinomas, 9 squamous cell carcinomas) of the nose, periorbital areas, and ears from 40 previously untreated patients (Group 1) and 57 patients who had undergone surgery (Group 2). The average dose was 55 Gy (range, 50-65 Gy) in Group 1 and 52 Gy (range, 50-60 Gy) in Group 2 (mean implantation times: 79 and 74 hours, respectively). We calculated survival rates and assessed functional and cosmetic results de visu.
  
  
  RESULTS
  Median age was 71 years (range, 17-97 years). There were 29 T1, 8 T2, 1 T3, and 2 Tx tumors in Group 1. Tumors were <2 cm in Group 2. Local control was 92.5% in Group 1 and 88% in Group 2 (median follow-up, 55 months; range, 6-132 months). Five-year disease-free survival was better in Group 1 (91%; range, 75-97) than in Group 2 (80%; range, 62-90; p = 0.23). Of the 34 patients whose results were reassessed, 8 presented with pruritus or epiphora; 1 Group 2 patient had an impaired eyelid aperture. Cosmetic results were better in Group 1 than in Group 2 with, respectively, 72% (8/11) vs. 52% (12/23) good results and 28 (3/11) vs. 43% (10/23) fair results.
  
  
  CONCLUSIONS
  Brachytherapy provided a high level of local control and good cosmetic results for facial periorificial skin carcinomas that pose problems of surgical reconstruction. Results were better for untreated tumors than for incompletely excised tumors or tumors recurring after surgery.
authors.affiliation: Department of Radiotherapy, CRLCC-Nantes-Atlantique, Saint Herblain, France. e-rio@nantes.fnclcc.fr
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Rio
authors.forename: Etienne
authors.initials: E
authors.lastname: Bardet
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferron
authors.forename: Patrick
authors.initials: P
authors.lastname: Peuvrel
authors.forename: Stéphane
authors.initials: S
authors.lastname: Supiot
authors.forename: Loic
authors.initials: L
authors.lastname: Campion
authors.forename: Claude Beauvillain
authors.initials: CB
authors.lastname: De Montreuil
authors.forename: Marc André
authors.initials: MA
authors.lastname: Mahe
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dreno
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015982:Bias; D001918:Brachytherapy / Q000379:methods*; D002280:Basal Cell Carcinoma / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D004428:Ear Neoplasms / Q000532:radiotherapy; D004431:Ear, External; D004954:Esthetics; D005142:Eyelid Neoplasms / Q000532:radiotherapy; D005153:Facial Neoplasms / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000532:radiotherapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007496:Iridium Radioisotopes